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Allergen-specific immunotherapy (SIT) offers a disease specific causative treatment by
modifying the allergen-specific immune response allowing tolerance to higher doses of
allergen and preventing progression of allergic diseases. It may be considered in patients
allergic to furry animals. Current mammalian allergy vaccines are still prepared from
relatively poorly defined allergen extracts and may induce immediate and late phase side
effects. Although the mechanisms of SIT are still not fully understood, the more recent
approaches report different strategies to reduce both allergen-specific IgE as well asT cell
reactivity. The availability of recombinant allergens and synthetic peptides from the mam-
malian species has contributed to formulating new allergy vaccines to improve SIT for furry
animal allergy.The majority of studies have focused on the major cat allergen Fel d 1 due to
its extensive characterization in terms of IgE andT cell epitopes and to its dominant role in
cat allergy. Here we review the most recent approaches, e.g., synthetic peptides, recom-
binant allergen derivatives, different hypoallergenic molecules, and recombinant allergens
coupled to virus-like particles or immunomodulatory substances as well as strategies tar-
geting the allergen to Fcγ receptors and the MHC class II pathway using a new route for
administration. Many of the new vaccines hold promise but only a few of them have been
investigated in clinical trials which will be the gold standard for evaluation of safety and
efficacy in allergic patients.
Keywords: allergen-specific immunotherapy, Fel d 1, mammalian allergens, recombinant allergens,T cell peptides,
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INTRODUCTION
Allergen-specific immunotherapy (SIT) offers a disease specific
causative treatment by inducing tolerance to the allergen and pre-
venting progression of allergic diseases, for example development
of asthma (1). Hence, patients who suffer from allergies where
avoidance is not possible such as house-dust mite respiratory aller-
gies are the prime candidates for SIT. Allergy to cats, dogs, or other
furry animals is common in society and the prevalence of sensi-
tization to pets has increased (2). Although the best treatment is
avoidance, it is often difficult to realize as well as not being well
accepted by the patients. Moreover allergens from furry animals,
e.g., the major cat allergen Fel d 1 is equally present in houses
without cats, in public places, public transport, day care centers,
and school rooms. So the question of SIT may be considered.
Allergen-specific immunotherapy for cat allergy has shown to be
more favorable than for, e.g., dog allergy (3). This may depend on
the standardization of cat extracts to Fel d 1, whereas dog extracts
may vary greatly in terms of allergen content (4).
The mechanisms of SIT are still not fully understood. The
clinical efficacy is associated with the production of allergen-
specific blocking immunoglobulin (Ig)G antibodies and the
generation of T regulatory cell (T regs) responses and secretion of
immunoregulatory cytokines such as interleukin 10 (5, 6); how-
ever, current SIT involves drawbacks such as treatment persistence,
due to the long treatment duration both with subcutaneous SIT
and sublingual immunotherapy (7). Furthermore, SIT of today
can induce adverse reactions ranging from mild symptoms to
life-threatening anaphylaxis and even death (8).
Allergy vaccines of today are still made from crude allergen
extracts, which are not well-defined. Since the structures of the
most common allergen molecules are now available, well-defined
recombinant and synthetic allergy vaccines can be generated
allowing targeting specific mechanisms of allergic disease without
increasing their allergenicity (9–11). Many of these new mole-
cular approaches concern pollen allergens. It has been shown
that SIT with the recombinant major birch allergen Bet v 1 is
equally effective as SIT with birch pollen extract or natural puri-
fied Bet v 1 (12). In this review, we describe different approaches
for new vaccines, e.g., recombinant allergen derivatives, different
hypoallergenic molecules, and recombinant allergens coupled to
virus-like particles or to immunomodulatory substances. Studies
being available concern principally evaluation of the cat major
allergen, either in animal models or in allergic patients.
GENERAL CONCEPTS TO INCREASE SAFETY OF ALLERGY
VACCINES
Side effects are related to the production of allergen-specific IgE
antibodies but can also be mediated by the allergen-specific T
cells. Several studies during the last years have used an allergen-
unrelated carrier molecule, which provides T cell help for the
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production of IgG antibodies but avoid the activation of allergen-
specific T cells. This approach would reduce T cell mediated side
effects. Different strategies to reduce both IgE as well as allergen-
specific T cell epitopes have been reported. These approaches will
lead to less IgE and T cell-mediated side effects (11, 13).
- Strategies targeting allergen-specific T cells by using T cell
epitope-containing peptides (synthetic molecules produced by
chemical synthesis), which give no IgE-mediated activation of
effector cells.
- Strategies reducing allergen-specific IgE reactivity, but conserv-
ing T cell reactivity.
- Strategies based on carrier-bound fusion proteins using pep-
tides. These allergen derived peptides are obtained from the
IgE-binding sites of the allergen but contain no or reduced
allergen-specific T cell epitopes and exhibit no or strongly
reduced IgE reactivity. The peptides are fused to an allergen-
unrelated viral carrier molecule and expressed as recombinant
proteins. This technology was promoted by the Vienna group
and a grass-pollen allergy vaccine based on carrier-bound pep-
tides of the four major grass-pollen allergens is now under
evaluation in a clinical phase II trial (11, 13–15).
Several other strategies for improving SIT have been described
in the studies published within the last years: e.g., targeting the
allergen to Fcγ receptors (16), targeting the MHC class II path-
way (17), linking allergens to CpG-containing nucleotides (18, 19)
or to carbohydrate-based particles (20), and co-administrating
allergens with immunomodulatory substances such as vitamin D3
(21, 22). DNA vaccines favoring specific Th1 responses may also
be used with different adjuvants such as CpG. mRNAs encoding
allergens are another possible strategy, which would improve the
safety of therapeutic nucleic acid-based vaccines. Moreover, dif-
ferent routes for SIT have been investigated using recombinant
allergens especially sublingual, epicutaneous, and intra-lymphatic
delivery of the allergen (23).
Table 1 provides a summary of these approaches that have been
applied for furry animal allergen SIT. It is interesting to note that
the majority of studies have focused on the major cat allergen Fel
d 1 due to its dominant role in cat allergy and to its extensively
characterization in terms of IgE and T cell epitopes.
T CELL PEPTIDES
T cell peptides were originally designed to modulate allergen-
specific T cell responses without IgE-mediated activation of effec-
tor cells (35). Following preclinical studies (36), a series of clin-
ical trials were performed to evaluate the safety and efficacy of
two polypeptides from the major cat allergen Fel d 1. Initially,
patients received a subcutaneous injection weekly for 4 weeks
with an equimolecular mixture of the peptides (ALLERVAX CAT;
Immunologic Pharmaceutical Corporation, Waltham, MA, USA,
an equimolar combination of two 27-aminoacid synthetic pep-
tides), 7.5, 75, and 750µg, or placebo. Significant improvements in
lung and nasal symptoms were observed in the high dose group but
many adverse events occurred several hours after peptide injection
(37). A subsequent multicenter study in which patients received
eight injections of 750µg of vaccine reported only modest clinical
improvement and immediate and late side effects were observed
Table 1 | Concepts and strategies for improving SIT for mammalian allergy.
Technologies Specific approaches Reference
Synthetic molecules Peptides
Mixture of 12 short peptides Oldfield et al. (24)a
Mixture of 7 short peptides Worm et al. (25)a, Patel et al. (26)a
Recombinant
molecules
Hypoallergens
Mutants Mus m 1 Ferrari et al. (27)
Hybrids Fel d 1 duplicated T cell epitopes
and disruption of disulfide bounds
Saarne et al. (28)
Random mutation Fel d 1 Nilsson et al. (29)
Peptide carrier fusion proteins
Derived virus particles Qß-Fel d 1 Schmitz et al. (30)
Pre-S domain of hepatitis B Fel d 1 peptides fused to Pre-S Niespodziana et al. (31)
Conjugation with
immunomodulatory
molecules
Fcγ receptor Truncated IgG Fcγ Fel d 1 Zhu et al. (16)
Truncated invariant chain peptide+
transactivator of transcription
MAT-Fel d 1 Martinez-Gomez et al. (17), Senti et al. (32)a
Vitamin D3 Fel d 1-Vitamin D3 Jeffery et al. (33), Grundström et al. (22)
Carbohydrate-based particles CBP-Fel d 1 Neimert-Andersson et al. (20), Thunberg et al. (34)
MAT, modular antigen transporter; CBP, carbohydrate-based particle.
aClinical studies.
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(38). Further developments using a mixture of 12 short peptides
comprising the majority of the T cell epitopes from Fel d 1 demon-
strated that changes in the quality of life of the active treated
group versus the placebo group, but isolated late asthmatic reac-
tions were still observed (24). In a recent study, a new vaccine
was developed consisting of a mixture of seven immunodominant
peptides (ToleroMune cat®, also known as cat PAD, Circassia Ltd,
Oxford, UK), which were selected on the basis of MHC-binding
characteristics. This approach allowed reducing the number of
peptides without substantially compromising population cover-
age. The safety and tolerability of the vaccine was evaluated in a
phase IIa study (25) where cat-allergic individuals were given a
single dose of the vaccine either intradermally or subcutaneously.
Inhibition of the late cutaneous reaction was considered as a sur-
rogate of clinical efficacy and 3 nmol was determined as the best
concentration for intradermally desensitization. Treatment was
performed in patients with cat-induced allergic rhinoconjunctivi-
tis and in an environmental exposure chamber they were exposed
to cat allergen before and after therapy. The clinical efficacy was
observed after 18–22 weeks and 50–54 weeks after the start of the
treatment and the highest dose of cat PAD (6 nmol 4 weeks apart,
compared to 3 nmol 2 weeks apart) gave the greatest efficacy. The
treatment effect was apparent on nasal and ocular symptoms and
persisted 9 months later without any further retreatment (26).
Other clinical studies should confirm these encouraging results.
T cell peptides containing major allergen epitopes have been
generated from the primary structures of other mammalian aller-
gens such as Can f 1 (39), Bos d 2 (40), and Equ c 1 (41) but the
potential application of these molecules in allergic patients have
not been investigated.
RECOMBINANT HYPOALLERGENIC DERIVATIVES
Hypoallergenic derivatives are characterized by a strongly reduced
IgE reactivity. The IgE-binding epitopes of Fel d 1 have been mod-
ified through disruption of disulfide bonds and duplication of T
cell epitopes. Three of the modified Fel d 1 derivatives displayed
a strong reduction in allergenicity with 400–900 times lower IgE-
binding capacity (hypoallergens) compared to wild-type Fel d 1
(28). The therapeutic capacity of the hypoallergen with the most
reduced IgE reactivity was evaluated in a mouse model for cat
allergy and by skin tests on cat-allergic patients. An induction of
Fel d 1-specific IgG antibodies with capacity of blocking patients’
IgE to rFel d 1 and a reduction in airway responsiveness was noted.
Furthermore, the hypoallergen showed a tendency of reduced SPT
reactivity compared to rFel d in seven cat-allergic patients (42).
Other hypoallergenic mutants of rFel d 1 have been generated
by the introduction of random mutated allergen sequences and
the selection of derivatives with a maintained tertiary structure
by phage display using IgE antibodies from cat-allergic patients.
The mutants had a lower IgE-binding and T cell activation capac-
ity and could induce strong IgG-anti Fel d 1 protective responses
by mouse immunization experiments. Thus they should be good
candidates for safe alternatives for SIT (29).
Furthermore, in search of a vaccine for mouse allergy a
structure-guided single point mutation has been performed for
Mus m 1, the major mouse allergen which is an urinary protein.
This mutation induced a spatial rearrangement of aromatic side
chains and a lower allergenic activity although the T cell reactivity
was preserved (27).
PEPTIDE CARRIER FUSION PROTEINS
One strategy to improve SIT has been to couple allergens to
the bacteriophage Qß-derived virus-like particles. In mice, one
injection of Qß coupled to Fel d 1 induced a Fel d 1-specific
IgG response, and reduced anaphylactic reactions after rFel d 1
challenge (30). However, the chemical coupling process might be
difficult to standardize for vaccine production.
Another carrier protein, the Pre-S domain of hepatitis B virus
has been evaluated more recently (31). The cat hypoallergen
vaccine was produced by fusion of Pre-S of hepatitis B to two
non-allergenic Fel d 1 derived peptides. This approach has shown
to eliminate both IgE-mediated and T cell mediated side effects.
The T cell help comes from a Fel d 1-unrelated carrier protein,
the Pre-S domain of hepatitis B virus, which contains antigenic
sites for both B and T cells (43). The recombinant fusion pro-
tein exhibited more than 1000-fold reduction in allergenic activity
compared with rFel d 1 (31). After immunization of mice and
rabbits the fusion protein induced Fel d 1-specific IgG antibodies,
which inhibited IgE-binding of cat-allergic patients to Fel d 1. In
addition, the T cell responses in immunized mice were specific
for Pre-S and very low for Fel d 1. This vaccine has to be further
evaluated in clinical studies to confirm its promising qualities.
CONJUGATION TO MOLECULES WITH
IMMUNOMODULATORY FUNCTIONS
A chimeric human–cat fusion protein composed of a truncated
human IgG Fc gamma 1 and Fel d 1 has been proposed for a new
approach of SIT (16). This conjugate induced a dose dependent
inhibition of Fel d 1 driven IgE histamine release from cat-allergic
donors’ basophiles and from sensitized human cord-blood derived
mast cells. The vaccine potential was also demonstrated in a mouse
model for cat allergy (16, 44).
A new technology called modular antigen translocation (MAT)
has been applied to Fel d 1 to enhance immunogenicity and
safety of SIT. By attaching a truncated invariant chain peptide,
and a transactivator of transcription peptide to allergens, they
are converted into cytoplasmic proteins targeting the MHC class
II pathway (17). MAT fusion of rFel d 1 has shown to enhance
protective antibody and Th1 responses in mice, while reducing
human basophil degranulation (17). A recent paper has described
a phase I/IIa, randomized, placebo-controlled, and double-blind
trial, using this construct by intra-lymphatic injections in cat dan-
der allergic patients (20 patients were randomized) (32). The intra-
lymphatic route has shown to reduce both the number of allergen
injections as well as the allergen dose, improving both efficacy
and safety of SIT (45). Three monthly injections with increasing
doses of MAT-Fel d 1 elicited no adverse events and there was
significant increase in allergen tolerance after nasal provocation.
Regulatory T cell responses were stimulated and IL10 cytokine
secretion and increased cat dander specific IgG4 production were
observed. This clinical study represents the first immunotherapy
trial with a recombinant cat allergen. It is also a major improve-
ment over classical immunotherapy due to improved safety, low
allergen doses, few injections, and a short treatment period. This
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promising vaccination approach has to be confirmed in larger
patient studies and also by assessing efficacy on reduction of
symptoms and medication use and long term follow-up.
1,25-Dihydrovitamin D3 has been shown to induce dendritic
cells with tolerogenic properties, thus, increasing regulatory T cell
responses (33). In an attempt to use this effect,VD3 was covalently
coupled to rFel d 1 and tested in a mouse model for cat allergy
(22). rFel d 1 VD3 was superior to rFel d 1 in reducing airway
inflammation, and airway hyperresponsiveness, and in producing
allergen-specific IgG blocking antibodies.
rFel d 1 has also been covalently coupled to carbohydrate-based
particles (CBP) for targeting of dendritic cells and enhanced adju-
vanticity in SIT (34). This approach was evaluated in a mouse
model for cat allergy (20). CBP-rFel d 1 treated mice showed
reduced features of allergic inflammation and increased allergen-
specific IgM and IgG responses. In a prophylactic protocol it
was also shown that CPB rFel d 1 prevents the induction of
airway inflammation possibly through the induction of allergen-
specific IgG and IgM and by a prolonged tissue exposure to rFel
d 1 (34).
CONCLUSION
Better characterization of recombinant allergens from mammalian
species has contributed to formulate new allergy vaccines to
improve SIT for patients allergic to furry animals. The identi-
fication of the major allergens in allergen sources is essential for
generating vaccines, which may replace the natural allergen extract
(11, 46). This explains in part why a majority of the new furry ani-
mal allergy vaccines have been restricted to the major cat allergen
Fel d 1. Further studies are needed to point out which allergen com-
ponent/s are needed for treatment of furry animal allergy, taking
in account the great variability of commercial extracts regarding
their allergen contents. This is especially true for dog allergens (4)
where the panel of allergens so far is incomplete. Several studies
presented here explore new concepts for improving the safety of
SIT, by using different approaches and various technologies. How-
ever, only a few of them have been investigated in clinical trials,
which will be the gold standard for evaluation of safety and efficacy
in allergic patients.
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